MedCity News August 22, 2024
By integrating digitization and machine learning, there is an opportunity to deliver personalized care to all patients and scale precision dosing with minimal physician involvement, maximizing the effectiveness and accessibility of these drugs.
GLP-1 drugs have taken the industry by storm, but real-world evidence is showing that a significant proportion of patients are discontinuing treatment courses, many attributing this to intolerable side effects. By integrating digitization and machine learning, there is an opportunity to deliver personalized care to all patients and scale precision dosing with minimal physician involvement, maximizing the effectiveness and accessibility of these drugs.
GLP-1 receptor agonist drugs, such as well-known brands Ozempic, Wegovy, Saxenda, Mounjaro and Zepbound, initially developed for Type 2 diabetes are game changers, greatly...
Today's Sponsors
Today's Sponsor